Lavipharm S.A Market Cap ($287.04 Million)
Market Cap & Net Worth: Lavipharm S.A (LAVI)
Lavipharm S.A market cap. Lavipharm S.A (AT:LAVI) has a market capitalization of $287.04 Million (€245.52 Million) as of November 1, 2026. Listed on the AT stock exchange, this Greece-based company holds position #14740 globally and #41 in its home market, demonstrating a 2.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lavipharm S.A's stock price €1.54 by its total outstanding shares 169043561 (169.04 Million). Also see LAVI cash flow conversion for how efficiently the company converts equity into cash flow.
Lavipharm S.A Market Cap History (2015–2026)
Lavipharm S.A market cap history from 2015 to 2026. Data shows growth from $77.25 Million to $303.56 Million (10.17% CAGR). Check Lavipharm S.A (LAVI) stock price for real-time trading data and today's change.
Lavipharm S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lavipharm S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Lavipharm S.A annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.97x
Lavipharm S.A's market cap is 2.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.49x
Lavipharm S.A's market cap is 17.49 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $77.25 Million | $26.37 Million | -$7.07 Million | 2.93x | N/A |
| 2016 | $47.47 Million | $31.14 Million | $3.66 Million | 1.52x | 12.97x |
| 2017 | $90.51 Million | $31.81 Million | $12.93 Million | 2.85x | 7.00x |
| 2018 | $77.25 Million | $34.06 Million | $1.25 Million | 2.27x | 61.85x |
| 2019 | $121.40 Million | $33.59 Million | $5.33 Million | 3.61x | 22.79x |
| 2020 | $259.39 Million | $37.64 Million | $2.17 Million | 6.89x | 119.81x |
| 2021 | $320.08 Million | $39.72 Million | $1.72 Million | 8.06x | 185.77x |
| 2022 | $75.89 Million | $46.01 Million | $834.00K | 1.65x | 90.99x |
| 2023 | $157.31 Million | $47.84 Million | $1.87 Million | 3.29x | 84.08x |
| 2024 | $157.12 Million | $52.95 Million | $8.98 Million | 2.97x | 17.49x |
Competitor Companies of LAVI by Market Capitalization
Companies near Lavipharm S.A in the global market cap rankings as of November 1, 2026. Also see LAVI asset base for a full breakdown of the balance sheet.
Key companies related to Lavipharm S.A by market ranking:
- Medicon Hellas S.A. (AT:MEDIC): Ranked #26452 globally with a market cap of $12.15 Million USD ( €10.40 Million EUR).
- Agora Inc (NASDAQ:API): Ranked #14731 globally with a market cap of $287.57 Million USD.
- Guangdong Jialong Food Co Ltd (SHE:002495): Ranked #14732 globally with a market cap of $287.51 Million USD ( CN¥1.96 Billion CNY).
- Kung Long Batteries Industrial Co Ltd (TW:1537): Ranked #14741 globally with a market cap of $286.98 Million USD ( NT$9.11 Billion TWD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #26452 | Medicon Hellas S.A. | AT:MEDIC | $12.15 Million | €3.00 |
| #14731 | Agora Inc | NASDAQ:API | $287.57 Million | $4.39 |
| #14732 | Guangdong Jialong Food Co Ltd | SHE:002495 | $287.51 Million | CN¥2.10 |
| #14741 | Kung Long Batteries Industrial Co Ltd | TW:1537 | $286.98 Million | NT$111.00 |
Market Capitalization of Lavipharm S.A (2015–2026)
Market capitalization of Lavipharm S.A from 2015 to today. Between 2015 and today, Lavipharm S.A's market cap moved from $77.25 Million to $ 303.56 Million, with a yearly change of 10.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €303.56 Million | +58.35% |
| 2025 | €191.70 Million | +22.01% |
| 2024 | €157.12 Million | -0.13% |
| 2023 | €157.31 Million | +107.29% |
| 2022 | €75.89 Million | -76.29% |
| 2021 | €320.08 Million | +23.40% |
| 2020 | €259.39 Million | +113.66% |
| 2019 | €121.40 Million | +57.15% |
| 2018 | €77.25 Million | -14.65% |
| 2017 | €90.51 Million | +90.67% |
| 2016 | €47.47 Million | -38.55% |
| 2015 | €77.25 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Lavipharm S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $287.04 Million USD |
| MoneyControl | $287.04 Million USD |
| MarketWatch | $287.04 Million USD |
| marketcap.company | $287.04 Million USD |
| Reuters | $287.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lavipharm S.A
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs,… Read more